In Vitro Cytotoxicity of GC Sequence Directed Alkylating Agents Related to Distamycin

Journal of Medicinal Chemistry

Volumn 36, Issue 7, 1993, Pages 863-870

  Lee, Moses ^a   Rhodes, Andrea L ^a   Wyatt, Michael D ^a   D'Incalci, Maurizio ^b   Forrow, Stephen ^c   Hartley, John A ^c  

^a FURMAN UNIVERSITY   (United States)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAMIDE; ALKYLATING AGENT; CHLORMETHINE; CYTOSINE; DISTAMYCIN A DERIVATIVE; DNA; FORMAMIDE; GUANOSINE; IMIDAZOLE DERIVATIVE; POLY(DEOXYADENYLATE DEOXYTHYMIDYLATE); POLYDEOXYRIBONUCLEOTIDE;

ARTICLE; CATTLE; CONTROLLED STUDY; CYTOTOXICITY; DNA ALKYLATION; DNA CROSS LINKING; DNA DRUG COMPLEX; DRUG BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; THYMUS;

ALKYLATING AGENTS; ANIMAL; CATTLE; CIRCULAR DICHROISM; DISTAMYCINS; DNA; HUMAN; IMIDAZOLES; STRUCTURE-ACTIVITY RELATIONSHIP; SUPPORT, U.S. GOV'T, NON-P.H.S.; TUMOR CELLS, CULTURED;

EID: 0027502899     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm00059a011     Document Type: Article

References (49)

1. Molecular Aspects of Anticancer Drug Action; Neidle, S., Waring, M., Eds.; MacMillan Pub. Co.: London, 1983.
2. Molecular Mechanisms of Carcinogenic and Antitumor Activity; Chagas, C., Pullman, B., Eds.; Adenine Press: New York, 1987.
3. Kohn, K. W.; Hartley, J. A.; Mattes, W. B. Mechanism of DNA Sequence Selective Alkylation of Guanine-N7 Positions by Nitrogen Mustards. Nucl. Acids Res. 1987, 15, 10531–10549.
4. Miller, P. S.; Ts'o, P. O. P. A New Approach to Chemotherapy Based on Molecular Biology and Nucleic Acid Chemistry: Matagen (Masking Tape for Gene Expression). Anticancer Drug Des. 1987, 2, 117–128.
5. Hurley, L. H. DNA and Associated Targets for Drug Design. J. Med. Chem. 1989, 32, 2027–2033.
6. Hurley, L. H.; Boyd, F. L. Approaches Toward the Design of Sequence Specific Drugs for DNA. Annu. Rep. Med. Chem. 1987, 22, 259–268.
7. Lown, J. W. Lexitropsins: Rational Design of DNA Sequence Reading Agents as Novel Anticancer Agents and Potential Cellular Probes. Anticancer Drug Des. 1988, 3, 25–40.
8. Barbacid, M. ras Genes. Annu. Rev. Biochem. 1987, 56, 779–872.
9. Mattes, W. A.; Hartley, J. A.; Kohn, K. W.; Matheson, D. W. GC Rich Sequences in Genomes as Targets for DNA Alkylation. Carcinogenesis 1988, 9, 2065–2072.
10. Hartley, J. A.; Lown, J. W.; Mattes, W. B.; Kohn, K. W. DNA Sequence Specificity of Antitumor Agents: Oncogenes as possible Targets for Cancer Therapy. Acta Oncol. 1988, 27, 503–506.
11. Ischii, S.; Kadonaga, J. T.; Tjian, R.; Brady, J. N.; Merlino, G. T.; Patsan, I. Binding of the Sp 1 Transcription Factor by the Human Harvey ros 1 Proto-oncogene Promoter. Science 1986, 232, 1410–1412.
12. Karlin. S. Significant Potential Secondary Structure in the Epstein Barr Virus Genome. Proc. Natl. Acad. Sci. U.S.A. 1986, 83, 6915–6919.
13. Burkitt, D. Cancer 1987, 20, 756.
14. Zeigler, J. L. Burkitt's Lymphoma. New Engl. J. Med. 1981, 305, 735–745.
15. Hartley, J. A. Mechanisms of Sequence Selective Modifications by Alkylating Agents. In Molecular Basis of Specificity in Nucleic Acid-Drug Interactions; Kluwer Acad. Pub.: Boston, 1990; pp 512–530.
16. Krowicki, K.; Lee, M.; Hartley, J. A.; Ward, B.; Kissinger, K.; Skorobogaty, A.; Dabrowiak, J. C.; Lown, J. W. Molecular Recognition between Oligopeptides and Nucleic Acids-Rational Design of Sequence Specific DNA Binding Agents. In Structure and Expression; Sarma, R. H., Sarma, M. H., Eds.; Adenine Press: New York, 1988; Vol. 2, pp 251–271.
17. Zimmer, C.; Wahnert, U. Nonintercalating DNA Binding Ligands: Specificity of the Interaction and their use as Tools in Biophysical, Biochemical and Biological Investigations of the Genetic Material. Prog. Biophys. Molec. Biol. 1986, 47, 31–112.
18. Dervan, P. B. Design of Sequence-Specific DNA Binding Molecules. Science 1986, 232, 464–471.
19. Barbieri, B.; Giuliani, C.; Pezzoni, G.; Lazzari, E.; Arcamone, F.; Mongelli, N. In-vivo Antitumor Activity of FCE 24517, a Novel Distamycin A Derivative with Specificity for AT Rich Sequences of DNA. Proc. Am. Cancer Soc. 1989, 29, 330.
20. Broggini, M.; Ballinary, D.; Spinelli, L.; Geroni, C.; Spreafico, F.; D'Incalci, M. Studies on the Mode of Action of the New Distamycin Derivative FCE24517. Proc. Am. Cancer Soc. 1990, 31, 348.
21. Arcamone, F.; et al. Synthesis, DNA Binding Properties, and Antitumor Activity of Novel Distamycin Derivatives. J. Med. Chem. 1989, 32, 774–778.
22. Lee, H. H.; Boyd, M.; Gravatt, G. L.; Denny, W. A. Pyrazole Analogues of the Pyrrolecarboamide Antitumor Antibiotics: Synthesis, DNA Binding and Antitumor Properties. Anticancer Drug Des. 1991, 6, 501–517.
23. Verweig, J.; Pinedo, H. M. Mitomycin C: Mechanism of Action, Usefulness and Limitations. Anticancer Drugs 1990, 1, 5–13.
24. Millard, J. T.; Weidner, M. F.; Stanley, R.; Hopkins, P. B. Determination of the Cross-linking Sequence Specificity of Reductively Activated Mitomycin C at Single Nucleotide Resolution: Deoxyguanosine Residues at CpG are Cross-linked Preferentially. J. Am. Chem. Soc. 1990, 112, 3637–3641.
25. Hurley, L. H.; Needham-VanDevanter, D. R. Covalent Binding of Antitumor Antibiotics in the Minor Groove of DNA. Mechanism of Action of CC-1065 and the Pyrrolo(1,4)benzodiazepines. Acc. Chem. Res. 1986, 19, 230–237.
26. Bose, D. S.; Thompson, A. S.; Ching, J.; Hartley, J. A.; Berardini, M. D.; Jenkins, T. C.; Neidle, S.; Hurley, L. H.; Thurston, D. E. Rational Design of a Highly Efficient Irreversible DNA InterStrand Cross-Linking Agent Based on the Pyrrolobenzodiazepine Ring System. J. Am. Chem. Soc. 1992, 114, 4939–4941.
27. Farmer, J. D., Jr.; Rudnicki, S. M.; Suggs, J. W. Synthesis and DNA Crosslinking Ability of a Dimeric Anthramycin Analog. Tetrahedron Lett. 1988, 29, 5105–5108.
28. Hahn, F. E. In Antibiotics III. Mechanisms of Action of Antimicrobial and Antitumor Agents; Corcoran, J. W., Hahn, F. E., Eds.; Springer-Verlag: New York, 1975; pp 79–100.
29. Kopka, M. L.; Yoon, C.; Goodsell, D.; Pjura, P.; Dickerson, R. E. The Molecular Origin of DNA-Drug Specificity of Netropsin and Distamycin. Proc. Natl. Sci. U.S.A. 1985, 82, 1376–1380.
30. Pullman, A.; Pullman, B. Molecular Electrostatic Potential of the Nucleic Acids. Quart. Rev. Biophys. 1981, 14, 289–380.
31. Kissinger, K.; Krowicki, K.; Dabrowiak, J. C.; Lown, J. W. Molecular Recognition between Oligopeptides and Nucleic Acids: Monocationic Imidazole Lexitropsins that Display Enhanced GC Sequence Dependent DNA Binding. Biochemistry 1987, 26, 5590–5598.
32. 1H-NMR Studies. Nucl. Acids Res. 1987, 16, 665–684.
33. Lee, M.; Krowicki, K.; Hartley, J. A.; Pon, R. T.; Lown, J. W. Molecular Recognition between Oligopeptides and Nucleic Acid: Influence of van der Waals Conntacts in Determining the 3′-Terminus of DNA Read by Monocationic Lexitropsins. J. Am. Chem. Soc. 1988, 110, 3641–3649.
34. Taylor, J. S.; Schultz, P. G.; Dervan, P. B. DNA Affinity Cleaving. Tetrahedron 1984, 40, 457–465.
35. 1H-NMR and MPE Footprinting Studies. Biochemistry, submitted.
36. Elderfield, R. C.; Liao, T. K. Synthesis of Potential Anticancer Agents. XII. Nitrogen Mustards for p-Aminobenzoic Acid Derivatives. J. Org. Chem. 1961, 26, 4996–4997.
37. LePecq, J.-B.; Paoletti, C. A Fluorescent Complex between Ethidium Bromide and Nucleic Acids. J. Mol. Biol. 1967, 27, 87–106.
38. Morgan, A. R.; Lee, J. S.; Pulleyblank, D. F.; Murray, N. L.; Evans, D. H. Ethidium Fluorescence Assays. Part 1. Physiochemical Studies. Nucl. Acids Res. 1979, 7, 547–569.
39. Luck, G.; Zimmer, C.; Reinert, K. E.; Arcamone, F. Specific Interactions of Distamycin A and Its Analogues with (A. T) Rich and (G.C) Rich Duplex Regions of DNA and Deoxypolynucleotides. Nucl. Acids Res. 1977, 4, 2655–2670.
40. Lown, J. W. New Approaches to the Study of the Mechanism of Action of Antitumor Antibiotics. Acc. Chem. Res. 1982, 15, 381–387.
41. Zimmer, C.; Wahnert, U. Nonintercalating DNA Binding Ligands: Specificity of the Interaction and Their Use as Tools in Biophysical, Biochemical and Biological Investigations of the Genetic Material. Prog. Biophys. Molec. Biol. 1986, 47, 31–112.
42. Burckhardt, G.; Luck, G.; Zimmer, C.; Storl, J.; Krowicki, K.; Lown, J. W. Variation of DNA Sequence Specificity of DNA-oligopeptide Binding Ligands Related to Netropsin: Imidazole-Containing Lexitropsins. Biochim. Biophys. Acta 1989, 1009, 11–18.
43. Molecular Basis in Nucleic Acid-Drug Interactions; Pullman, B., Jortner, J., Eds.; Kluwer Academic Pub.: Boston, 1990.
44. Unpublished results. Hartley, J. A.; Berardini, M. D.; Souhami, R. L. An Agarose Gel Method for the Determination of DNA Interstrand Crosslinking Applicable to the Measurement of Total and ‘Second Arm’ Crosslinking Reactions. Anal. Biochem. 1991, 193, 131–134.
45. Boyd, M. R. Status of the NCI Preclinical Antitumor Drug Discovery Screen. Princ. Pract. Oncol. 1989, 3, 1–12.
46. Broggini, M.; Erba, E.; Ponti, M.; Ballinari, D.; Geroni, C.; Spreafico, F.; D'Incalci, M. Selective DNA Interaction of the Novel Distamycin Derivative FCE24517. Cancer Res. 1991, 51, 199–204.
47. Krowicki, K.; Balzarini, J.; De Clercq, E.; Newman, R. A.; Lown, J. W. Novel DNA Groove Binding Alkylators: Design, Synthesis, and Biological Evaluation. J. Med. Chem. 1988, 31, 341–345.
48. Debart, F.; Periguad, C.; Gosselin, D.; Mrani, D.; Rayner, B.; LeBer, P.; Auclair, C.; Balzarini, J.; CeClercq, E.; Paoletti, C.; Imbach, J.-L. Synthesis, DNA Binding, and Biological Evaluation of Synthetic Precursors and Novel Analogues of Netropsin. J. Med. Chem. 1989, 32, 1074–1083.
49. Carmichael, J.; De Graff, W. G.; Gazdar, A. F.; Minna, J. D.; Mitchell, J. B. Evaluation of a tetrazolium based semi-automated colorimetric assay. I: Assessment of chemosensitivity testing. Cancer Res. 1987, 47, 936.